Finerenone FDA Approval Status

FDA Approved: No
Generic name: finerenone
Company: Bayer HealthCare Pharmaceuticals Inc.
Treatment for: Chronic Kidney Disease and Type 2 Diabetes

Finerenone (BAY 94-8862) is an investigational, non-steroidal, selective mineralocorticoid receptor antagonist (MRA) in development for use in patients with chronic kidney disease and type 2 diabetes.

Finerenone has been shown to reduce many of the harmful effects of mineralocorticoid receptor (MR) overactivation, which is a driver of kidney and cardiovascular damage through inflammatory and fibrotic processes.

Development Timeline for finerenone

Date	Article
Nov  9, 2020	Bayer Submits Regulatory Applications for Investigational Drug Finerenone in the U.S. and the EU for Patients with Chronic Kidney Disease and Type 2 Diabetes
Jul  9, 2020	Bayer’s Finerenone Meets Primary Endpoint in Phase III FIDELIO-DKD Renal Outcomes Study in Patients With Chronic Kidney Disease and Type 2 Diabetes

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer